Maxim Group Initiates Coverage On Rein Therapeutics with Buy Rating, Announces Price Target of $4

Benzinga Newsdesk www.benzinga.com Neutral 57.8%

Neg 0% Neu 57.8% Pos 0%

Maxim Group analyst Jason McCarthy initiates coverage on Rein Therapeutics (NASDAQ:RNTX) with a Buy rating and announces Price Target of $4.